Prof. Fabio Pacelli
  • Chi sono
  • Patologie trattate
    • Patologia oncologica
    • Patologia benigna
  • Pubblicazioni
  • Videogallery
  • Dicono di me
  • Prenota una visita
  • Chi sono
  • Patologie trattate
    • Patologia oncologica
    • Patologia benigna
  • Pubblicazioni
  • Videogallery
  • Dicono di me
  • Prenota una visita

/Pubblicazioni/Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.

Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.

By Prof. Fabio Pacelli - In Pubblicazioni - 23 Luglio 2013

The American Surgeon

Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.

Am Surg. 2013 Feb;79(2):151-61.

Pacelli F, Sanchez AM, Covino M, Tortorelli AP, Bossola M, Valentini V, Gambacorta MA, Doglietto GB.

Departments of Surgical Sciences, Catholic University, School of Medicine, Rome, Italy.

Neoadjuvant chemoradiation (CRT), tailored mesorectal excision, and intraoperative radiotherapy (IORT) have become the leading measures for rectal cancer treatment. The objective of this study was to evaluate early and long-term results of a multimodal treatment model for rectal cancer followed by curative surgery. Prospectively collected hospital records of 338 patients surgically treated for rectal cancer between January 1998 and December 2008 were retrospectively reviewed. Patients with high rectum level cancers and those with middle and low rectum cancers with clinical stage T1 to T2 underwent surgery, whereas those with T3 to T4 and N+ disease at the middle and low rectum received neoadjuvant CRT in 96.2 per cent of cases. Short-course neoadjuvant radiotherapy was not considered for neoadjuvant treatment. Postoperative major complications and mortality rates were 12.7 and 2.3 per cent, respectively. Overall 5-year disease-specific and disease-free survival were 80 and 73.1 per cent, respectively, whereas local recurrence rate was 6.1 per cent. At multivariate analysis, nodal status and circumferential margin status were independently associated with poor survival; local recurrence rates were independently affected by nodal and marginal status and tumor stage. The extent of mesorectal excision should be tailored depending on tumor location and the use of neoadjuvant chemotherapy, combined with IORT in advanced middle and low rectal cancer, leading to remarkable tumor downstaging with excellent prognosis in responding patients.
Torna alle pubblicazioni

Share

  • Google+
  • Twitter
  • Facebook
← Immediate definitive prosthetic reconstruction in patients with ptotic breasts
Multivisceral resection for locally advanced gastric cancer: an italian multicenter observational study. →

Ultimi articoli

  • Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis
    Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis

    Surgical Oncology; 2020 34:270-275. Di G...

  • Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases of pancreatic origin
    Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases of pancreatic origin

    International Journal of Surgery Case Re...

  • Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma
    Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma

    Therapeutic Advances in Medical Oncology...

  • Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies using new hybrid CO2 system: preliminary experience in referral center
    Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies using new hybrid CO2 system: preliminary experience in referral center

    Updates in Surgery; 2019 71:555-560. Cia...

  • The Cholegas trial: long-term results of prophylactic cholecystectomy during gastrectomy for cancer‚ a randomized-controlled trial
    The Cholegas trial: long-term results of prophylactic cholecystectomy during gastrectomy for cancer‚ a randomized-controlled trial

    Gastric Cancer; 2019 22:632-639. Bencini...

Archivi

  • Febbraio 2021
  • Febbraio 2018
  • Gennaio 2018
  • Novembre 2016
  • Ottobre 2016
  • Luglio 2013
  • Maggio 2012

CONTATTI

Prof. Fabio Pacelli
E-mail: fabio.pacelli@policlinicogemelli.it

Policlinico Universitario "A. Gemelli"
Direttore UOC Chirurgia del peritoneo e del retroperitoneo
Largo F. Vito, 1 - 00168 Roma
Tel. (+39) 06 30157255

PRENOTA UNA VISITA

Visite private - Tel. (+39) 06 88818881

Visite online - Videoconsulto@policlinicogemelli.it

In alternativa utilizza la nostra FORM DI CONTATTO per inviarci un messaggio

Copyright © 2012-. All Rights Reserved - Powered by Apiweb Srl